Symptomatic treatment of vertigo, iterative with or without cochlear sign


This form is reserved for patients requiring a dosage of 48 mg per day of betahistine. In other cases, use a lower dosage

BETAHISTINE ZYDUS FRANCE 24 mg tablet will be given 1 tablet twice a day, preferably in the middle of the meal.
Children and adolescents

The use of BETAHISTINE ZYDUS FRANCE 24 mg in children and adolescents under 18 years of age is not recommended due to lack of data, safety and efficacy

Elderly subjects

Since the available data are limited, betahistine should be used with caution in the elderly.

There is no data available in patients with renal insufficiency

Hepatic impairment

There is no data available in patients with hepatic impairment

Duration of processing

The duration of the recommended treatment is 2 to 3 months, to be renewed, possibly, depending on the course of the disease, in continuous or discontinuous cures. >
Mode of administration

The tablets must be swallowed without being crunched with a glass of water.

Class: Pharmacotherapeutic: ANTIVERTIGINOUS.

(N: nervous system, central).
The mechanism of action of betahistine is partially known.

In vitro, betahistine, facilitates histaminergic transmission by its agonist effect, partial on the H 1 receptors, and an effect, antagonist of receptors of type H 3.
< Code>
Betahistin decreases, electrical activity of polysynaptic neurons, vestibular nuclei after I.V. administration in the animal

Betahistine has no effect sedative

Not applicable.

· Hypersensitivity to any of the components of this medication

· Gastroduodenal ulcer in thrust.

· Pheochromocytoma.

In patients with asthma, the administration of betahistine requires special surveillance (risk of bronchoconstriction).

Betahistine does not constitute the appropriate treatment of the following pathologies

· Benign paroxysmal vertigo

· Vertigo in relation to a nervous system disorder,

Without object.

Not applicable.

Symptoms analogous to those caused by histamine

Administer antihistamine treatment


Studies in the animal have not demonstrated any teratogenic effect. In the absence of teratogenic effect in animals, a malformative effect in the human species is not expected. Indeed, to date, the substances responsible for malformations in the human species have been shown to be teratogenic in animals during studies, well conducted on two species
< Br>

There is at present no relevant or sufficient data to evaluate a possible malformative or fetotoxic effect of betahistin when administered during pregnancy

Therefore, as a precautionary measure, it is preferable not to use betahistin during pregnancy.

In the absence of data on the passage through breast milk, the risk is not known, therefore breast-feeding is not recommended, while taking betahistine.

Most common adverse reactions

· Gastralgia, nausea, vomiting, dryness, mouth, diarrhea

More rarely

· Headache, asthenia, somnolence, hypersensitivity reactions.


· Thrombocytopenia, elevation of transaminases.

Reporting of suspected adverse reactions

The reporting of suspected adverse effects after authorization of the drug is important. It provides continuous monitoring of the benefit / risk ratio of the drug. Health professionals report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (Ansm) and network of Regional Pharmacovigilance Centers -
Symptomatic treatment of vertigo, iterative with or without cochlear sign